鼻内给予抗炎药治疗有望缓解多发性硬化症的进展

2020-10-21 MedSci原创 MedSci原创

鼻内给药不会进入循环系统,需要的药量更少,可以直接递送至大脑,并且药物分解速度也不会很快。

阿尔伯塔大学的临床前研究表明,鼻内给予抗炎药有助于缓解多发性硬化症的疾病进展。

研究结果显示,通过鼻内给药向小鼠提供抗炎药可以避免脑细胞受损,从而有效缓解疾病进展。MS是一种破坏性疾病,发病机制不清晰且无法治愈。阿尔伯塔大学Power教授的实验室寻求更好地了解这种疾病,从而开发出有效的治疗方法。

炎症小体是细胞内的多蛋白复合体,过度激活后会引起强烈的炎症反应,进而促进多种炎症性疾病的进展,例如MS。Power实验室探究了炎性小体效应蛋白caspase-1的抑制剂VX-765,是否可以成为MS患者的强效候选疗法。

Role of NLRP3 inflammasome in inflammatory bowel diseases

炎性小体信号通路(图片来源:https://www.wjgnet.com/1007-9327/full/v25/i33/4796.htm)

在小鼠模型中,Power将VX-765溶解在液体中,然后将混合物注入鼻子。研究表明,鼻内给药可有效抑制脱髓鞘、轴突损伤和丢失。MS中髓磷脂和神经的丢失是不可逆的过程,因此任何有助于减缓或阻止这种情况发生的疗法都是MS研究的重要进步。

鼻内给药不会进入循环系统,需要的药量更少,可以直接递送至大脑,而且分解速度也不会很快。

原始出处:

https://www.firstwordpharma.com/node/1766856?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1983143, encodeId=61c9198314351, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jun 13 20:06:13 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890173, encodeId=0a0a18901e3dc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Mar 28 15:06:13 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893899, encodeId=d9458938995f, content=积分真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4d2326628, createdName=1225f870m98(暂无昵称), createdTime=Fri Oct 23 07:55:56 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346783, encodeId=ad511346e833b, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Oct 23 01:06:13 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893484, encodeId=0f8b8934846c, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Oct 21 10:17:17 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1983143, encodeId=61c9198314351, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jun 13 20:06:13 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890173, encodeId=0a0a18901e3dc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Mar 28 15:06:13 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893899, encodeId=d9458938995f, content=积分真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4d2326628, createdName=1225f870m98(暂无昵称), createdTime=Fri Oct 23 07:55:56 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346783, encodeId=ad511346e833b, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Oct 23 01:06:13 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893484, encodeId=0f8b8934846c, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Oct 21 10:17:17 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
    2021-03-28 jml2009
  3. [GetPortalCommentsPageByObjectIdResponse(id=1983143, encodeId=61c9198314351, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jun 13 20:06:13 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890173, encodeId=0a0a18901e3dc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Mar 28 15:06:13 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893899, encodeId=d9458938995f, content=积分真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4d2326628, createdName=1225f870m98(暂无昵称), createdTime=Fri Oct 23 07:55:56 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346783, encodeId=ad511346e833b, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Oct 23 01:06:13 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893484, encodeId=0f8b8934846c, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Oct 21 10:17:17 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
    2020-10-23 1225f870m98(暂无昵称)

    积分真好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1983143, encodeId=61c9198314351, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jun 13 20:06:13 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890173, encodeId=0a0a18901e3dc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Mar 28 15:06:13 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893899, encodeId=d9458938995f, content=积分真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4d2326628, createdName=1225f870m98(暂无昵称), createdTime=Fri Oct 23 07:55:56 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346783, encodeId=ad511346e833b, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Oct 23 01:06:13 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893484, encodeId=0f8b8934846c, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Oct 21 10:17:17 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1983143, encodeId=61c9198314351, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jun 13 20:06:13 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890173, encodeId=0a0a18901e3dc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sun Mar 28 15:06:13 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893899, encodeId=d9458938995f, content=积分真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4d2326628, createdName=1225f870m98(暂无昵称), createdTime=Fri Oct 23 07:55:56 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346783, encodeId=ad511346e833b, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Oct 23 01:06:13 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893484, encodeId=0f8b8934846c, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Oct 21 10:17:17 CST 2020, time=2020-10-21, status=1, ipAttribution=)]
    2020-10-21 医鸣惊人

    认真学习了

    0

相关资讯

FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta(ofatumumab),只需每月注射一次

Kesimpta是全人源抗CD20单抗,与特立氟胺相比,显示出优异的疗效和相似的安全性。

Cell Biol Int:鼻内递送SDF-1α预处理的干细胞可改善杯多发性硬化症的再髓鞘化作用

多发性硬化症(MS)是一种中枢神经系统(CNS)的炎症和脱髓鞘疾病,可导致中年人残疾。高凋亡率和不适当的归巢是干细胞在细胞治疗中应用的限制。使用基质细胞衍生因子1α(SDF-1&alpha

Acta Neurol Scand:多发性硬化症患者补充维生素D3是否会增加其疾病的复发风险?

多个队列研究发现,低循环维生素D水平与活动性MRI病变和复发的多发性硬化症(RRMS)复发的风险增加相关。然而,随机对照的补充试验在其主要终点上是阴性的,而次要的MRI终点表明有抗炎作用。循环中神经丝

多发性硬化症药物或添新成员:FDA批准ANK-700治疗多发性硬化症的IND

瑞士生物技术公司Anokion SA近日宣布,美国食品药品监督管理局(FDA)已批准抗原特异性药物ANK-700治疗多发性硬化症(MS)的IND申请。

NATURE:肠道微生物可以加剧多发性硬化症

越来越多的证据表明,肠道微生物在自身免疫性疾病中具有致病作用,包括多发性硬化症。对实验性自身免疫性脑脊髓炎(多发性硬化症的动物模型)以及人类的研究,已将肠道微生物联系到多发性硬化症的发展或严重程度中。

EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症:所有剂量组均取得积极结果

生物制药公司Atara的研究性药物ATA188治疗多发性硬化症(MS)取得积极进展。ATA188是一款异基因EBV特异性T细胞免疫疗法。